Protalix Biotherapeutics Company Profile (NYSEMKT:PLX)

About Protalix Biotherapeutics (NYSEMKT:PLX)

Protalix Biotherapeutics logoProtalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:PLX
  • CUSIP: N/A
  • Web: www.protalix.com
Capitalization:
  • Market Cap: $110.68 million
  • Outstanding Shares: 133,355,000
Average Prices:
  • 50 Day Moving Avg: $0.60
  • 200 Day Moving Avg: $0.77
  • 52 Week Range: $0.26 - $1.51
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.61
  • P/E Growth: -0.10
Sales & Book Value:
  • Annual Revenue: $16 million
  • Price / Sales: 6.92
  • Book Value: ($0.16) per share
  • Price / Book: -5.19
Profitability:
  • EBITDA: ($30,580,000.00)
Misc:
  • Average Volume: 577,623 shs.
  • Beta: 0.95
 

Frequently Asked Questions for Protalix Biotherapeutics (NYSEMKT:PLX)

What is Protalix Biotherapeutics' stock symbol?

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PLX."

How were Protalix Biotherapeutics' earnings last quarter?

Protalix Biotherapeutics Inc (NYSEMKT:PLX) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.02. The firm had revenue of $6.36 million for the quarter, compared to analysts' expectations of $5.05 million. View Protalix Biotherapeutics' Earnings History.

Where is Protalix Biotherapeutics' stock going? Where will Protalix Biotherapeutics' stock price be in 2017?

3 equities research analysts have issued 1 year target prices for Protalix Biotherapeutics' stock. Their forecasts range from $1.00 to $5.00. On average, they expect Protalix Biotherapeutics' stock price to reach $3.67 in the next year. View Analyst Ratings for Protalix Biotherapeutics.

Who are some of Protalix Biotherapeutics' key competitors?

How do I buy Protalix Biotherapeutics stock?

Shares of Protalix Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protalix Biotherapeutics' stock price today?

One share of Protalix Biotherapeutics stock can currently be purchased for approximately $0.83.


MarketBeat Community Rating for Protalix Biotherapeutics (NYSEMKT PLX)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  136 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  263
MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Protalix Biotherapeutics (NYSEMKT:PLX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.67
Consensus Price Target History for Protalix Biotherapeutics (NYSEMKT:PLX)
Price Target History for Protalix Biotherapeutics (NYSEMKT:PLX)
Analysts' Ratings History for Protalix Biotherapeutics (NYSEMKT:PLX)
Show:
DateFirmActionRatingPrice TargetDetails
8/10/2017HC WainwrightSet Price TargetBuy$5.00View Rating Details
5/23/2017Rodman & RenshawReiterated RatingBuy$5.00View Rating Details
12/15/2016MackieReiterated RatingBuy$1.00View Rating Details
9/6/2016Jefferies Group LLCLower Price TargetBuy$1.75 -> $0.80View Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for Protalix Biotherapeutics (NYSEMKT:PLX)
Earnings by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
Earnings History by Quarter for Protalix Biotherapeutics (NYSEMKT PLX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/20176/30/2017($0.04)($0.06)$5.05 million$6.36 millionViewListenView Earnings Details
5/10/2017Q1 17($0.09)($0.07)$2.55 million$2.89 millionViewN/AView Earnings Details
8/8/2016Q2 16($0.08)($0.11)$1.34 million$1.77 millionViewN/AView Earnings Details
3/8/2016Q415($0.29)$3.50 million$4.40 millionViewN/AView Earnings Details
11/9/2015Q3 15($0.08)($0.04)$5.00 million$4.30 millionViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.05)$6.40 million$3.78 millionViewN/AView Earnings Details
5/7/2015Q1 15($0.08)($0.06)$8.20 million$4.39 millionViewN/AView Earnings Details
8/7/2014($0.07)($0.07)$9.63 million$2.43 millionViewN/AView Earnings Details
5/8/2014($0.07)($0.08)$8.25 million$6.70 millionViewN/AView Earnings Details
3/13/2014Q413($0.02)($0.12)$5.54 million$2.36 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Protalix Biotherapeutics (NYSEMKT:PLX)
Current Year EPS Consensus Estimate: $-0.23 EPS
Next Year EPS Consensus Estimate: $-0.18 EPS

Dividends

Dividend History for Protalix Biotherapeutics (NYSEMKT:PLX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Protalix Biotherapeutics (NYSEMKT:PLX)
Insider Trades by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
Institutional Ownership by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
Insider Trades by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Moshe ManorCEOBuy50,000$0.81$40,500.00View SEC Filing  
12/2/2016Camber Capital Management LlcMajor ShareholderSell2,500,000$0.32$800,000.00View SEC Filing  
12/14/2015Yossi MaimonCFOBuy10,000$0.78$7,800.00View SEC Filing  
10/19/2015Camber Capital Management LlcMajor ShareholderBuy4,000,423$1.00$4,000,423.00View SEC Filing  
8/15/2013Alfred AkirovDirectorSell112,330$5.05$567,266.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Protalix Biotherapeutics (NYSEMKT:PLX)
Latest Headlines for Protalix Biotherapeutics (NYSEMKT:PLX)
Source:
DateHeadline
finance.yahoo.com logoProtalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
finance.yahoo.com - October 19 at 7:38 AM
finance.yahoo.com logoProtalix Biotherapeutics Inc (PLX) Shares Skyrocket – Here’s Why
finance.yahoo.com - October 19 at 7:38 AM
americanbankingnews.com logoProtalix Biotherapeutics Inc (PLX) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 15 at 9:02 PM
prnewswire.com logoTechnical Snapshots for These Biotech Stocks -- ImmunoCellular Therapeutics, Protalix BioTherapeutics, Synthetic ... - PR Newswire (press release)
www.prnewswire.com - September 22 at 1:31 PM
globenewswire.com logoProtalix Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 5 at 10:27 PM
finance.yahoo.com logoProtalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 8:20 AM
finance.yahoo.com logoEdited Transcript of PLX earnings conference call or presentation 9-Aug-17 12:30pm GMT
finance.yahoo.com - August 11 at 7:36 AM
americanbankingnews.com logoProtalix Biotherapeutics Inc (NYSEMKT:PLX) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - August 10 at 2:36 PM
seekingalpha.com logoProtalix BioTherapeutics' (PLX) CEO Moshe Manor on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 10 at 6:54 AM
finance.yahoo.com logoProtalix BioTherapeutics Reports 2017 Second Quarter Results and Provides Corporate Update
finance.yahoo.com - August 10 at 6:54 AM
finance.yahoo.com logoProtalix posts 2Q profit
finance.yahoo.com - August 10 at 6:54 AM
finance.yahoo.com logoInvestor Network: Protalix BioTherapeutics, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 6:28 AM
globenewswire.com logoProtalix BioTherapeutics to Hold Second Quarter 2017 Financial ... - GlobeNewswire (press release)
globenewswire.com - August 1 at 2:34 AM
finance.yahoo.com logoProtalix BioTherapeutics to Hold Second Quarter 2017 Financial Results and Corporate Update Conference Call on August 9, 2017
finance.yahoo.com - August 1 at 2:34 AM
globenewswire.com logoProtalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 ... - GlobeNewswire (press release)
globenewswire.com - July 27 at 6:27 AM
marketwatch.com logoConcurrently the Company Completes Private Placement of $10 Million Convertible Notes
www.marketwatch.com - July 26 at 6:26 AM
finance.yahoo.com logoProtalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 million Notes Maturing February 2022
finance.yahoo.com - July 26 at 6:26 AM
seekingalpha.com logoProCellEx Has The Potential To Upend The Biopharmaceutical Sector - Seeking Alpha
seekingalpha.com - July 2 at 6:30 AM
seekingalpha.com logoProtalix BioTherapeutics (PLX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 8:08 PM
nasdaq.com logoAre Options Traders Betting on a Big Move in Protalix BioTherapeutics (PLX) Stock? - Nasdaq
www.nasdaq.com - May 31 at 1:07 PM
globenewswire.com logoProtalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - May 27 at 2:30 AM
streetinsider.com logoProtalix BioTherapeutics (PLX) Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in CF - StreetInsider.com
www.streetinsider.com - May 25 at 12:35 AM
seekingalpha.com logoProtalix BioTherapeutics Is Positioned Well For The Future
seekingalpha.com - April 21 at 12:23 AM
streetinsider.com logoProtalix BioTherapeutics (PLX) Announces New Data Demonstrating Positive Effect of PRX-102 - StreetInsider.com
www.streetinsider.com - April 19 at 9:51 AM
seekingalpha.com logoProtalix BioTherapeutics: The DNase Treatment For Cystic Fibrosis And Opportunity For Profits - Seeking Alpha
seekingalpha.com - April 14 at 6:57 AM
rttnews.com logoAERI's Rocket Hits Target, ENTL Gets FDA Nod, NOVN Jumps On Positive Trial Data
www.rttnews.com - April 13 at 9:30 AM
streetinsider.com logoProtalix BioTherapeutics (PLX) Phase II Trial of alidornase alfa Shows Positive Results in CF
www.streetinsider.com - April 13 at 9:30 AM
streetinsider.com logoProtalix BioTherapeutics (PLX) Phase II Trial of alidornase alfa Shows Positive Results in CF - StreetInsider.com
www.streetinsider.com - April 12 at 11:56 PM
seekingalpha.com logoProtalix BioTherapeutics Looks Solid With Strong Pipeline - Protalix ... - Seeking Alpha
seekingalpha.com - March 27 at 6:43 PM
seekingalpha.com logoProtalix BioTherapeutics: Exploring Ulcerative Colitis - Seeking Alpha
seekingalpha.com - March 16 at 8:31 AM
biz.yahoo.com logoQ4 2016 Protalix Biotherapeutics Inc Earnings Release - Time Not Supplied
biz.yahoo.com - March 16 at 8:31 AM
biz.yahoo.com logoPROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 16 at 8:31 AM
globenewswire.com logoProtalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16 ... - GlobeNewswire (press release)
globenewswire.com - March 9 at 7:06 PM
bizjournals.com logoTechnical Reports on Biotech Stocks -- Juno Therapeutics, Protalix BioTherapeutics, ImmunoGen, and ContraVir Pharma
www.bizjournals.com - February 23 at 8:58 AM
seekingalpha.com logoProtalix BioTherapeutics: New Institutional Ownership Swells Ahead Of Major Catalysts
seekingalpha.com - February 21 at 5:35 PM
biz.yahoo.com logoPROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - February 16 at 6:52 PM
us.rd.yahoo.com logoProtalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders
us.rd.yahoo.com - February 14 at 11:33 PM
globenewswire.com logoProtalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders - GlobeNewswire (press release)
globenewswire.com - February 14 at 11:33 PM
globenewswire.com logoProtalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017 - GlobeNewswire (press release)
www.globenewswire.com - February 14 at 4:21 AM
seekingalpha.com logoProtalix continues up move, shares ahead 27% - Seeking Alpha
seekingalpha.com - February 14 at 4:21 AM
finanznachrichten.de logoGainers & Losers Of The Day: ZSAN, PLSE, XOMA, SAGE, CBIO...
www.finanznachrichten.de - February 13 at 11:19 PM
us.rd.yahoo.com logoProtalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017
us.rd.yahoo.com - February 13 at 11:19 PM
us.rd.yahoo.com logo8:42 am Protalix BioTherapeutics outperforming ahead of the open after previewing its presentations at this week's Annual WORLDSymposium (2/13-2/17)
us.rd.yahoo.com - February 13 at 11:19 PM
globenewswire.com logoProtalix BioTherapeutics to Participate in the 13th Annual ... - GlobeNewswire (press release)
globenewswire.com - February 13 at 9:14 AM
zacks.com logoProtalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7%
www.zacks.com - January 30 at 8:28 AM
streetinsider.com logoKnight Therapeutics Acquires 6.2M Shares of Protalix ... - StreetInsider.com
www.streetinsider.com - January 30 at 12:44 AM

Social

Chart

Protalix Biotherapeutics (PLX) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.